Evidence map›Paper›PMID 35102456›Full record

ReviewArchives of virology2022

Virus interactions with the actin cytoskeleton-what we know and do not know about SARS-CoV-2.

Malgorzata Kloc, Ahmed Uosef, Jarek Wosik, Jacek Z Kubiak, Rafik M Ghobrial

Open access · bronzeAbstract readReview
In one paragraph

Review in Archives of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. SARS-CoV-2 S assembly into virions facilitated by host ERM proteins.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  7. Article
  8. Pathogen-Mediated Cell Fusion and Actin Cytoskeleton.Advances in experimental medicine and biology · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. The Impact ofViruses · 2025
    Article
  13. Article
  14. Myosin IXB protects immune cells from virus infection.The Journal of general virology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Malgorzata KlocThe Houston Methodist Research Institute, Houston, TX, USA. mkloc@houstonmethodist.org.ORCID http://orcid.org/0000-0002-5192-8584
Ahmed UosefThe Houston Methodist Research Institute, Houston, TX, USA.
Jarek WosikElectrical and Computer Engineering Department, University of Houston, Houston, TX, 77204, USA.
Jacek Z KubiakMilitary Institute of Medicine, Laboratory of Molecular Oncology and Innovative Therapies, Department of Oncology, 04-141, Warsaw, Poland.
Rafik M GhobrialThe Houston Methodist Research Institute, Houston, TX, USA.
Houston Methodist · USCentre National de la Recherche Scientifique · FRUniversity of Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The actin cytoskeleton and actin-dependent molecular and cellular events are responsible for the organization of eukaryotic cells and their functions. Viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), depend on host cell organelles and molecular components for cell entry and propagation. Thus, it is not surprising that they also interact at many levels with the actin cytoskeleton of the host. There have been many studies on how different viruses reconfigure and manipulate the actin cytoskeleton of the host during successive steps of their life cycle. However, we know relatively little about the interactions of SARS-CoV-2 with the actin cytoskeleton. Here, we describe how the actin cytoskeleton is involved in the strategies used by different viruses for entry, assembly, and egress from the host cell. We emphasize what is known and unknown about SARS-CoV-2 in this regard. This review should encourage further investigation of the interactions of SARS-CoV-2 with cellular components, which will eventually be helpful for developing novel antiviral therapies for mitigating the severity of COVID-19.

Indexed as

COVID-19Viruses, UnclassifiedActin CytoskeletonAntiviral AgentsHumansSARS-CoV-2Antiviral Agents

Identifiers

PMID35102456
PMCPMC8803281
OpenAlexW4210697389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.